L’Oréal backs REACH
This article was originally published in The Rose Sheet
Executive Summary
French beauty company reiterates its support for the European Commission's Registration, Evaluation and Authorization of Chemicals project, which is "perfectly in line with L'Oréal's sustainable development strategy," firm notes in Sept. 6 release. "For several years, prior to the publication of REACH, L'Oréal had already adopted a responsible approach to consumer health and demonstrated its commitment to environmental protection issues," company says. The firm notes it is conducting a "large-scale" program aimed at updating its catalog of ingredients used in the manufacturing of products. The European Parliament will conduct talks this fall on the proposal for REACH, which requires manufacturers or importers of more than one ton per year of a chemical to register with a yet-to-be established European Chemicals Agency and provide supporting data; the proposal was overhauled in 2003 (1"The Rose Sheet" Nov. 3, 2003, p. 11)...
You may also be interested in...
EU Chemical Plan Overhaul Exempts Polymers, Reduces Burden Downstream
The European Commission's 1chemical testing proposal released Oct. 29 includes provisions to exempt certain polymers and reduce the burden on downstream users in an effort to address industry concerns
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.